![Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma | Leukemia Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2017.173/MediaObjects/41375_2017_Article_BFleu2017173_Fig1_HTML.jpg)
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma | Leukemia
AQUAZZURA - Candy on our feet. Our eye-catching 'Pom Pom 105' sandals, available at NET-A-PORTER. #SS16 Photo credit: David Glauso | Facebook
![Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma | Research To Practice Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2012/3/4/Slide4.jpg)
Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma | Research To Practice
![Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis | BMC Cancer | Full Text Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis | BMC Cancer | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-018-4722-x/MediaObjects/12885_2018_4722_Fig3_HTML.png)
Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis | BMC Cancer | Full Text
![Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma | Leukemia Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fleu.2014.60/MediaObjects/41375_2014_Article_BFleu201460_Fig1_HTML.jpg)
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma | Leukemia
![A Systematic Review and Network Meta-Analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide Refractory Multiple Myeloma - ScienceDirect A Systematic Review and Network Meta-Analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide Refractory Multiple Myeloma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497118717217-gr1.jpg)